Rickets Companies

Cellexis Their vitamin D3 analog, KX-001, demonstrated positive results in a Phase 2b clinical trial for treating vitamin D-deficiency rickets, paving the way for potential market entry.

Abello Therapeutics Their investigational treatment for mineral-related rickets, AT-007, successfully completed a Phase 1 clinical trial, advancing development towards further studies.

Valneva Their first-ever chikungunya vaccine, VLA1553 (Ixchiq®), received both FDA and EMA approvals in Q4 2023, marking a significant milestone for the market and offering an option for preventing rickets-associated Chikungunya complications.

Bayer Secured conditional marketing authorization in the EU for their HIF-1 inhibitor, BAY1895344, for treating adult-onset hypoxic-ischemic encephalopathy, which can lead to secondary rickets-like bone deformities.

Genea Their innovative endometrial biopsy tool with integrated gene expression analysis allows for personalized assessment of vitamin D deficiency and rickets risk, promoting early intervention.

• Koninklijke DSM N.V. (the Netherlands)


• Nestlé S.A. (Switzerland)


• ADM Alliance Nutrition, Inc. (U.S.)


• Groupe Danone S.A. (France)


• Abbott (U.S.)


• Kraft Foods Group, Inc. (U.S.)


• Merck & Co., Inc. (U.S.)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Pfizer (U.S.)


• Sun Pharmaceutical Industries Ltd (India)